Shore Capital Reaffirms “Hold” Rating for GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc (LON:GSK)‘s stock had its “hold” rating reissued by analysts at Shore Capital in a report issued on Thursday.
Several other brokerages also recently weighed in on GSK. Beaufort Securities lifted their price objective on shares of GlaxoSmithKline plc from GBX 1,750 ($22.60) to GBX 2,000 ($25.83) and gave the company a “buy” rating in a research report on Thursday, June 1st. Liberum Capital reiterated a “buy” rating and issued a GBX 1,900 ($24.54) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday, June 6th. S&P Global set a GBX 1,500 ($19.37) price objective on shares of GlaxoSmithKline plc and gave the company a “sell” rating in a research report on Tuesday, June 6th. Jefferies Group LLC lifted their price objective on shares of GlaxoSmithKline plc from GBX 1,800 ($23.25) to GBX 1,900 ($24.54) and gave the company a “buy” rating in a research report on Friday, June 16th. Finally, UBS AG set a GBX 1,600 ($20.66) price objective on shares of GlaxoSmithKline plc and gave the company a “neutral” rating in a research report on Friday, June 9th. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of GBX 1,705.90 ($22.03).
Shares of GlaxoSmithKline plc (LON GSK) traded down 1.79% during midday trading on Thursday, hitting GBX 1454.00. 14,085,046 shares of the stock were exchanged. The firm has a 50-day moving average price of GBX 1,507.18 and a 200-day moving average price of GBX 1,610.52. The company’s market cap is GBX 71.07 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,446.50 and a 12-month high of GBX 1,745.56.
In other news, insider Victoria Whyte sold 4,820 shares of GlaxoSmithKline plc stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of GBX 1,693 ($21.86), for a total value of £81,602.60 ($105,388.87). Also, insider Patrick Vallance bought 861 shares of the company’s stock in a transaction dated Friday, July 14th. The stock was purchased at an average cost of GBX 1,618 ($20.90) per share, for a total transaction of £13,930.98 ($17,991.71). Over the last three months, insiders bought 3,152 shares of company stock worth $5,055,023.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.